Immune Signatures Distinguish Pure and Mixed Sepsis in Critical COVID-19: A Retrospective Cohort Study.
Li Xiong, Huan Tang, Qian Xie...
https://pubmed.ncbi.nlm.nih.gov/40831520Actively Recruiting
Age: 18Years - 90Years
All Genders
ID06491966
Comparative Analysis of Clinical Outcomes and Inflammatory Responses in Viral Versus Bacterial Sepsis: A Retrospective Cohort Study in ICU Patients
Led by Sichuan Provincial People's Hospital · Updated on 2024-07-09
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are comparing clinical outcomes and inflammatory responses between patients with viral sepsis caused by COVID-19 and those with bacterial sepsis. This observational cohort study analyzes data from ICU patients admitted between July 2021 and December 2023 at Sichuan Provincial People's Hospital. The goal is to identify reliable biomarkers and diagnostic methods to improve patient care through personalized approaches. The study includes two groups: one with patients confirmed to have viral sepsis via RT-PCR for SARS-CoV-2, and another with patients diagnosed with bacterial sepsis confirmed by positive bacterial cultures. Data collected include demographic information, clinical outcomes such as mortality rate and ICU stay length, inflammatory markers like cytokines, and treatment details including the use of mechanical ventilation, CRRT, ECMO, and antibiotics. Participants' clinical data, inflammatory marker levels, and treatment information are retrospectively analyzed. The research team evaluates outcomes such as 28-day mortality, length of ICU stay, and incidence of secondary infections. Advanced statistical methods assess the predictive value of biomarkers. This study aims to deepen understanding of sepsis types to guide future personalized diagnosis and treatment strategies.
CONDITIONS
Brief Title
Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis
Who Can Participate
Age: 18Years - 90Years
All Genders
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with sepsis according to Sepsis 3.0 criteria
- Confirmed bacterial sepsis with positive bacterial cultures
- Confirmed viral sepsis with COVID-19 diagnosed by RT-PCR (viral group) or negative bacterial cultures (viral group)
- Aged 18 years or older
- Admitted to the ICU during the study period
You will not qualify if you...
- Mixed bacterial and viral infections
- Sepsis not meeting Sepsis 3.0 criteria
- Use of immunomodulatory therapies other than standard treatments
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Up to 28 days from ICU admission
Participants who underwent routine ICU care for sepsis are observed. Data collected includes clinical outcomes such as mortality rate and length of ICU stay, inflammatory markers, and treatment details like mechanical ventilation and antibiotic use.
Continuous monitoring during ICU stay up to 28 days
Trial Site Locations
Total: 1 location
1
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China, 610091
Actively Recruiting
Loading map...
Research Team
L
Lin Chen, doctor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here